Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Mueller-Hennessen, M; Lindahl, B; Giannitsis, E; Vafaie, M; Biener, M; Haushofer, AC; Seier, J; Christ, M; Alquézar-Arbé, A; deFilippi, CR; McCord, J; Body, R; Panteghini, M; Jernberg, T; Plebani, M; Verschuren, F; French, JK; Christenson, RH; Dinkel, C; Katus, HA; Mueller, C.
Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction.
Int J Cardiol. 2019; 276(1): 261-267. Doi: 10.1016/j.ijcard.2018.10.084
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Haushofer Alexander
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: We aimed to directly compare the diagnostic and prognostic performance of a dual maker strategy (DMS) with combined testing of copeptin and high-sensitivity (hs) cardiac troponin T (cTnT) at time of presentation with other algorithms for rapid rule-out of acute myocardial infarction (AMI). 922 patients presenting to the emergency department with suspected AMI and available baseline copeptin measurements qualified for the present TRAPID-AMI substudy. Diagnostic measures using the DMS (copeptin <10, <14 or < 20 pmol/L and hs-cTnT≤14 ng/L), the 1 h-algorithm (hs-cTnT<12 ng/L and change <3 ng/L at 1 h), as well as the hs-cTnT limit-of-blank (LoB, <3 ng/L) and -detection (LoD, <5 ng/L) were compared. Outcomes were assessed as combined end-points of death and myocardial re-infarction. True-negative rule-out using the DMS could be achieved in 50.9%-62.3% of all patients compared to 35.0%, 45.3% and 64.5% using LoB, LoD or the 1 h-algorithm, respectively. The DMS showed NPVs of 98.1%-98.3% compared to 99.2% for the 1 h-algorithm, 99.4% for the LoB and 99.3% for the LoD. Sensitivities were 93.5%-94.8%, as well as 96.8%, 98.7% and 98.1%, respectively. Addition of clinical low-risk criteria such as a HEART-score ≤ 3 to the DMS resulted in NPVs and sensitivities of 100% with a true-negative rule-out to 33.8%-41.6%. Rates of the combined end-point of death/MI within 30 days ranged between 0.2% and 0.3% for all fast-rule-out protocols. Depending on the applied copeptin cut-off and addition of clinical low-risk criteria, the DMS might be an alternative to the hs-cTn-only-based algorithms for rapid AMI rule-out with comparable diagnostic measures and outcomes. Copyright © 2018. Published by Elsevier B.V.
Find related publications in this database (using NLM MeSH Indexing): Aged -; Algorithms -; Biomarkers - blood; Electrocardiography -; Female -; Glycopeptides - blood; Humans -; Immunoassay -; Male -; Middle Aged -; Myocardial Infarction - blood; Myocardial Infarction - diagnosis; Predictive Value of Tests -; Prognosis -; Prospective Studies -; Time Factors -; Troponin T - blood
Find related publications in this database (Keywords): Copeptin; High-sensitivity cardiac troponin T; Rapid AMI rule-out; Dual-marker strategy